Global Recurrent Glioblastoma Multiforme Treatment Market Growth (Status and Outlook) 2022-2028

1.1 Market Introduction

1.2 Years Considered

1.3 Research Objectives

1.4 Market Research Methodology

1.5 Research Process and Data Source

1.6 Economic Indicators

1.7 Currency Considered

2 Executive Summary

2.1 World Market Overview

2.1.1 Global Recurrent Glioblastoma Multiforme Treatment Market Size 2017-2028

2.1.2 Recurrent Glioblastoma Multiforme Treatment Market Size CAGR by Region 2017 VS 2022 VS 2028

2.2 Recurrent Glioblastoma Multiforme Treatment Segment by Type

2.2.1 AU-105

2.2.2 Axitinib

2.2.3 AXL-1717

2.2.4 AZD-7451

2.2.5 Others

2.3 Recurrent Glioblastoma Multiforme Treatment Market Size by Type

2.3.1 Recurrent Glioblastoma Multiforme Treatment Market Size CAGR by Type (2017 VS 2022 VS 2028)

2.3.2 Global Recurrent Glioblastoma Multiforme Treatment Market Size Market Share by Type (2017-2022)

2.4 Recurrent Glioblastoma Multiforme Treatment Segment by Application

2.4.1 Hospital

2.4.2 Clinic

2.4.3 Others

2.5 Recurrent Glioblastoma Multiforme Treatment Market Size by Application

2.5.1 Recurrent Glioblastoma Multiforme Treatment Market Size CAGR by Application (2017 VS 2022 VS 2028)

2.5.2 Global Recurrent Glioblastoma Multiforme Treatment Market Size Market Share by Application (2017-2022)

3 Recurrent Glioblastoma Multiforme Treatment Market Size by Player

3.1 Recurrent Glioblastoma Multiforme Treatment Market Size Market Share by Players

3.1.1 Global Recurrent Glioblastoma Multiforme Treatment Revenue by Players (2020-2022)

3.1.2 Global Recurrent Glioblastoma Multiforme Treatment Revenue Market Share by Players (2020-2022)

3.2 Global Recurrent Glioblastoma Multiforme Treatment Key Players Head office and Products Offered

3.3 Market Concentration Rate Analysis

3.3.1 Competition Landscape Analysis

3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)

3.4 New Products and Potential Entrants

3.5 Mergers & Acquisitions, Expansion

4 Recurrent Glioblastoma Multiforme Treatment by Regions

4.1 Recurrent Glioblastoma Multiforme Treatment Market Size by Regions (2017-2022)

4.2 Americas Recurrent Glioblastoma Multiforme Treatment Market Size Growth (2017-2022)

4.3 APAC Recurrent Glioblastoma Multiforme Treatment Market Size Growth (2017-2022)

4.4 Europe Recurrent Glioblastoma Multiforme Treatment Market Size Growth (2017-2022)

4.5 Middle East & Africa Recurrent Glioblastoma Multiforme Treatment Market Size Growth (2017-2022)

5 Americas

5.1 Americas Recurrent Glioblastoma Multiforme Treatment Market Size by Country (2017-2022)

5.2 Americas Recurrent Glioblastoma Multiforme Treatment Market Size by Type (2017-2022)

5.3 Americas Recurrent Glioblastoma Multiforme Treatment Market Size by Application (2017-2022)

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Recurrent Glioblastoma Multiforme Treatment Market Size by Region (2017-2022)

6.2 APAC Recurrent Glioblastoma Multiforme Treatment Market Size by Type (2017-2022)

6.3 APAC Recurrent Glioblastoma Multiforme Treatment Market Size by Application (2017-2022)

6.4 China

6.5 Japan

6.6 Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

7 Europe

7.1 Europe Recurrent Glioblastoma Multiforme Treatment by Country (2017-2022)

7.2 Europe Recurrent Glioblastoma Multiforme Treatment Market Size by Type (2017-2022)

7.3 Europe Recurrent Glioblastoma Multiforme Treatment Market Size by Application (2017-2022)

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 Middle East & Africa

8.1 Middle East & Africa Recurrent Glioblastoma Multiforme Treatment by Region (2017-2022)

8.2 Middle East & Africa Recurrent Glioblastoma Multiforme Treatment Market Size by Type (2017-2022)

8.3 Middle East & Africa Recurrent Glioblastoma Multiforme Treatment Market Size by Application (2017-2022)

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 Market Drivers, Challenges and Trends

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 Global Recurrent Glioblastoma Multiforme Treatment Market Forecast

10.1 Global Recurrent Glioblastoma Multiforme Treatment Forecast by Regions (2023-2028)

10.1.1 Global Recurrent Glioblastoma Multiforme Treatment Forecast by Regions (2023-2028)

10.1.2 Americas Recurrent Glioblastoma Multiforme Treatment Forecast

10.1.3 APAC Recurrent Glioblastoma Multiforme Treatment Forecast

10.1.4 Europe Recurrent Glioblastoma Multiforme Treatment Forecast

10.1.5 Middle East & Africa Recurrent Glioblastoma Multiforme Treatment Forecast

10.2 Americas Recurrent Glioblastoma Multiforme Treatment Forecast by Country (2023-2028)

10.2.1 United States Recurrent Glioblastoma Multiforme Treatment Market Forecast

10.2.2 Canada Recurrent Glioblastoma Multiforme Treatment Market Forecast

10.2.3 Mexico Recurrent Glioblastoma Multiforme Treatment Market Forecast

10.2.4 Brazil Recurrent Glioblastoma Multiforme Treatment Market Forecast

10.3 APAC Recurrent Glioblastoma Multiforme Treatment Forecast by Region (2023-2028)

10.3.1 China Recurrent Glioblastoma Multiforme Treatment Market Forecast

10.3.2 Japan Recurrent Glioblastoma Multiforme Treatment Market Forecast

10.3.3 Korea Recurrent Glioblastoma Multiforme Treatment Market Forecast

10.3.4 Southeast Asia Recurrent Glioblastoma Multiforme Treatment Market Forecast

10.3.5 India Recurrent Glioblastoma Multiforme Treatment Market Forecast

10.3.6 Australia Recurrent Glioblastoma Multiforme Treatment Market Forecast

10.4 Europe Recurrent Glioblastoma Multiforme Treatment Forecast by Country (2023-2028)

10.4.1 Germany Recurrent Glioblastoma Multiforme Treatment Market Forecast

10.4.2 France Recurrent Glioblastoma Multiforme Treatment Market Forecast

10.4.3 UK Recurrent Glioblastoma Multiforme Treatment Market Forecast

10.4.4 Italy Recurrent Glioblastoma Multiforme Treatment Market Forecast

10.4.5 Russia Recurrent Glioblastoma Multiforme Treatment Market Forecast

10.5 Middle East & Africa Recurrent Glioblastoma Multiforme Treatment Forecast by Region (2023-2028)

10.5.1 Egypt Recurrent Glioblastoma Multiforme Treatment Market Forecast

10.5.2 South Africa Recurrent Glioblastoma Multiforme Treatment Market Forecast

10.5.3 Israel Recurrent Glioblastoma Multiforme Treatment Market Forecast

10.5.4 Turkey Recurrent Glioblastoma Multiforme Treatment Market Forecast

10.5.5 GCC Countries Recurrent Glioblastoma Multiforme Treatment Market Forecast

10.6 Global Recurrent Glioblastoma Multiforme Treatment Forecast by Type (2023-2028)

10.7 Global Recurrent Glioblastoma Multiforme Treatment Forecast by Application (2023-2028)

11 Key Players Analysis

11.1 Boehringer Ingelheim GmbH

11.1.1 Boehringer Ingelheim GmbH Company Information

11.1.2 Boehringer Ingelheim GmbH Recurrent Glioblastoma Multiforme Treatment Product Offered

11.1.3 Boehringer Ingelheim GmbH Recurrent Glioblastoma Multiforme Treatment Revenue, Gross Margin and Market Share (2020-2022)

11.1.4 Boehringer Ingelheim GmbH Main Business Overview

11.1.5 Boehringer Ingelheim GmbH Latest Developments

11.2 Boston Biomedical, Inc.

11.2.1 Boston Biomedical, Inc. Company Information

11.2.2 Boston Biomedical, Inc. Recurrent Glioblastoma Multiforme Treatment Product Offered

11.2.3 Boston Biomedical, Inc. Recurrent Glioblastoma Multiforme Treatment Revenue, Gross Margin and Market Share (2020-2022)

11.2.4 Boston Biomedical, Inc. Main Business Overview

11.2.5 Boston Biomedical, Inc. Latest Developments

11.3 Bristol-Myers Squibb Company

11.3.1 Bristol-Myers Squibb Company Company Information

11.3.2 Bristol-Myers Squibb Company Recurrent Glioblastoma Multiforme Treatment Product Offered

11.3.3 Bristol-Myers Squibb Company Recurrent Glioblastoma Multiforme Treatment Revenue, Gross Margin and Market Share (2020-2022)

11.3.4 Bristol-Myers Squibb Company Main Business Overview

11.3.5 Bristol-Myers Squibb Company Latest Developments

11.4 Cantex Pharmaceuticals, Inc.

11.4.1 Cantex Pharmaceuticals, Inc. Company Information

11.4.2 Cantex Pharmaceuticals, Inc. Recurrent Glioblastoma Multiforme Treatment Product Offered

11.4.3 Cantex Pharmaceuticals, Inc. Recurrent Glioblastoma Multiforme Treatment Revenue, Gross Margin and Market Share (2020-2022)

11.4.4 Cantex Pharmaceuticals, Inc. Main Business Overview

11.4.5 Cantex Pharmaceuticals, Inc. Latest Developments

11.5 Cavion LLC

11.5.1 Cavion LLC Company Information

11.5.2 Cavion LLC Recurrent Glioblastoma Multiforme Treatment Product Offered

11.5.3 Cavion LLC Recurrent Glioblastoma Multiforme Treatment Revenue, Gross Margin and Market Share (2020-2022)

11.5.4 Cavion LLC Main Business Overview

11.5.5 Cavion LLC Latest Developments

11.6 Celldex Therapeutics, Inc.

11.6.1 Celldex Therapeutics, Inc. Company Information

11.6.2 Celldex Therapeutics, Inc. Recurrent Glioblastoma Multiforme Treatment Product Offered

11.6.3 Celldex Therapeutics, Inc. Recurrent Glioblastoma Multiforme Treatment Revenue, Gross Margin and Market Share (2020-2022)

11.6.4 Celldex Therapeutics, Inc. Main Business Overview

11.6.5 Celldex Therapeutics, Inc. Latest Developments

11.7 Coherus BioSciences, Inc.

11.7.1 Coherus BioSciences, Inc. Company Information

11.7.2 Coherus BioSciences, Inc. Recurrent Glioblastoma Multiforme Treatment Product Offered

11.7.3 Coherus BioSciences, Inc. Recurrent Glioblastoma Multiforme Treatment Revenue, Gross Margin and Market Share (2020-2022)

11.7.4 Coherus BioSciences, Inc. Main Business Overview

11.7.5 Coherus BioSciences, Inc. Latest Developments

11.8 Cortice Biosciences, Inc.

11.8.1 Cortice Biosciences, Inc. Company Information

11.8.2 Cortice Biosciences, Inc. Recurrent Glioblastoma Multiforme Treatment Product Offered

11.8.3 Cortice Biosciences, Inc. Recurrent Glioblastoma Multiforme Treatment Revenue, Gross Margin and Market Share (2020-2022)

11.8.4 Cortice Biosciences, Inc. Main Business Overview

11.8.5 Cortice Biosciences, Inc. Latest Developments

11.9 Eisai

11.9.1 Eisai Company Information

11.9.2 Eisai Recurrent Glioblastoma Multiforme Treatment Product Offered

11.9.3 Eisai Recurrent Glioblastoma Multiforme Treatment Revenue, Gross Margin and Market Share (2020-2022)

11.9.4 Eisai Main Business Overview

11.9.5 Eisai Latest Developments

11.10 Eli Lilly and Company

11.10.1 Eli Lilly and Company Company Information

11.10.2 Eli Lilly and Company Recurrent Glioblastoma Multiforme Treatment Product Offered

11.10.3 Eli Lilly and Company Recurrent Glioblastoma Multiforme Treatment Revenue, Gross Margin and Market Share (2020-2022)

11.10.4 Eli Lilly and Company Main Business Overview

11.10.5 Eli Lilly and Company Latest Developments

11.11 EnGeneIC Ltd

11.11.1 EnGeneIC Ltd Company Information

11.11.2 EnGeneIC Ltd Recurrent Glioblastoma Multiforme Treatment Product Offered

11.11.3 EnGeneIC Ltd Recurrent Glioblastoma Multiforme Treatment Revenue, Gross Margin and Market Share (2020-2022)

11.11.4 EnGeneIC Ltd Main Business Overview

11.11.5 EnGeneIC Ltd Latest Developments

11.12 ERC Belgium SA

11.12.1 ERC Belgium SA Company Information

11.12.2 ERC Belgium SA Recurrent Glioblastoma Multiforme Treatment Product Offered

11.12.3 ERC Belgium SA Recurrent Glioblastoma Multiforme Treatment Revenue, Gross Margin and Market Share (2020-2022)

11.12.4 ERC Belgium SA Main Business Overview

11.12.5 ERC Belgium SA Latest Developments

11.13 GenSpera, Inc.

11.13.1 GenSpera, Inc. Company Information

11.13.2 GenSpera, Inc. Recurrent Glioblastoma Multiforme Treatment Product Offered

11.13.3 GenSpera, Inc. Recurrent Glioblastoma Multiforme Treatment Revenue, Gross Margin and Market Share (2020-2022)

11.13.4 GenSpera, Inc. Main Business Overview

11.13.5 GenSpera, Inc. Latest Developments

11.14 Genzyme Corporation

11.14.1 Genzyme Corporation Company Information

11.14.2 Genzyme Corporation Recurrent Glioblastoma Multiforme Treatment Product Offered

11.14.3 Genzyme Corporation Recurrent Glioblastoma Multiforme Treatment Revenue, Gross Margin and Market Share (2020-2022)

11.14.4 Genzyme Corporation Main Business Overview

11.14.5 Genzyme Corporation Latest Developments

11.15 GW Pharmaceuticals Plc

11.15.1 GW Pharmaceuticals Plc Company Information

11.15.2 GW Pharmaceuticals Plc Recurrent Glioblastoma Multiforme Treatment Product Offered

11.15.3 GW Pharmaceuticals Plc Recurrent Glioblastoma Multiforme Treatment Revenue, Gross Margin and Market Share (2020-2022)

11.15.4 GW Pharmaceuticals Plc Main Business Overview

11.15.5 GW Pharmaceuticals Plc Latest Developments

11.16 ImmunoCellular Therapeutics, Ltd.

11.16.1 ImmunoCellular Therapeutics, Ltd. Company Information

11.16.2 ImmunoCellular Therapeutics, Ltd. Recurrent Glioblastoma Multiforme Treatment Product Offered

11.16.3 ImmunoCellular Therapeutics, Ltd. Recurrent Glioblastoma Multiforme Treatment Revenue, Gross Margin and Market Share (2020-2022)

11.16.4 ImmunoCellular Therapeutics, Ltd. Main Business Overview

11.16.5 ImmunoCellular Therapeutics, Ltd. Latest Developments

12 Research Findings and Conclusion

Table 1. Recurrent Glioblastoma Multiforme Treatment Market Size CAGR by Region (2017 VS 2022 VS 2028) & ($ Millions)

Table 2. Major Players of AU-105

Table 3. Major Players of Axitinib

Table 4. Major Players of AXL-1717

Table 5. Major Players of AZD-7451

Table 6. Major Players of Others

Table 7. Recurrent Glioblastoma Multiforme Treatment Market Size CAGR by Type (2017 VS 2022 VS 2028) & ($ Millions)

Table 8. Global Recurrent Glioblastoma Multiforme Treatment Market Size by Type (2017-2022) & ($ Millions)

Table 9. Global Recurrent Glioblastoma Multiforme Treatment Market Size Market Share by Type (2017-2022)

Table 10. Recurrent Glioblastoma Multiforme Treatment Market Size CAGR by Application (2017 VS 2022 VS 2028) & ($ Millions)

Table 11. Global Recurrent Glioblastoma Multiforme Treatment Market Size by Application (2017-2022) & ($ Millions)

Table 12. Global Recurrent Glioblastoma Multiforme Treatment Market Size Market Share by Application (2017-2022)

Table 13. Global Recurrent Glioblastoma Multiforme Treatment Revenue by Players (2020-2022) & ($ Millions)

Table 14. Global Recurrent Glioblastoma Multiforme Treatment Revenue Market Share by Player (2020-2022)

Table 15. Recurrent Glioblastoma Multiforme Treatment Key Players Head office and Products Offered

Table 16. Recurrent Glioblastoma Multiforme Treatment Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)

Table 17. New Products and Potential Entrants

Table 18. Mergers & Acquisitions, Expansion

Table 19. Global Recurrent Glioblastoma Multiforme Treatment Market Size by Regions 2017-2022 & ($ Millions)

Table 20. Global Recurrent Glioblastoma Multiforme Treatment Market Size Market Share by Regions (2017-2022)

Table 21. Americas Recurrent Glioblastoma Multiforme Treatment Market Size by Country (2017-2022) & ($ Millions)

Table 22. Americas Recurrent Glioblastoma Multiforme Treatment Market Size Market Share by Country (2017-2022)

Table 23. Americas Recurrent Glioblastoma Multiforme Treatment Market Size by Type (2017-2022) & ($ Millions)

Table 24. Americas Recurrent Glioblastoma Multiforme Treatment Market Size Market Share by Type (2017-2022)

Table 25. Americas Recurrent Glioblastoma Multiforme Treatment Market Size by Application (2017-2022) & ($ Millions)

Table 26. Americas Recurrent Glioblastoma Multiforme Treatment Market Size Market Share by Application (2017-2022)

Table 27. APAC Recurrent Glioblastoma Multiforme Treatment Market Size by Region (2017-2022) & ($ Millions)

Table 28. APAC Recurrent Glioblastoma Multiforme Treatment Market Size Market Share by Region (2017-2022)

Table 29. APAC Recurrent Glioblastoma Multiforme Treatment Market Size by Type (2017-2022) & ($ Millions)

Table 30. APAC Recurrent Glioblastoma Multiforme Treatment Market Size Market Share by Type (2017-2022)

Table 31. APAC Recurrent Glioblastoma Multiforme Treatment Market Size by Application (2017-2022) & ($ Millions)

Table 32. APAC Recurrent Glioblastoma Multiforme Treatment Market Size Market Share by Application (2017-2022)

Table 33. Europe Recurrent Glioblastoma Multiforme Treatment Market Size by Country (2017-2022) & ($ Millions)

Table 34. Europe Recurrent Glioblastoma Multiforme Treatment Market Size Market Share by Country (2017-2022)

Table 35. Europe Recurrent Glioblastoma Multiforme Treatment Market Size by Type (2017-2022) & ($ Millions)

Table 36. Europe Recurrent Glioblastoma Multiforme Treatment Market Size Market Share by Type (2017-2022)

Table 37. Europe Recurrent Glioblastoma Multiforme Treatment Market Size by Application (2017-2022) & ($ Millions)

Table 38. Europe Recurrent Glioblastoma Multiforme Treatment Market Size Market Share by Application (2017-2022)

Table 39. Middle East & Africa Recurrent Glioblastoma Multiforme Treatment Market Size by Region (2017-2022) & ($ Millions)

Table 40. Middle East & Africa Recurrent Glioblastoma Multiforme Treatment Market Size Market Share by Region (2017-2022)

Table 41. Middle East & Africa Recurrent Glioblastoma Multiforme Treatment Market Size by Type (2017-2022) & ($ Millions)

Table 42. Middle East & Africa Recurrent Glioblastoma Multiforme Treatment Market Size Market Share by Type (2017-2022)

Table 43. Middle East & Africa Recurrent Glioblastoma Multiforme Treatment Market Size by Application (2017-2022) & ($ Millions)

Table 44. Middle East & Africa Recurrent Glioblastoma Multiforme Treatment Market Size Market Share by Application (2017-2022)

Table 45. Key Market Drivers & Growth Opportunities of Recurrent Glioblastoma Multiforme Treatment

Table 46. Key Market Challenges & Risks of Recurrent Glioblastoma Multiforme Treatment

Table 47. Key Industry Trends of Recurrent Glioblastoma Multiforme Treatment

Table 48. Global Recurrent Glioblastoma Multiforme Treatment Market Size Forecast by Regions (2023-2028) & ($ Millions)

Table 49. Global Recurrent Glioblastoma Multiforme Treatment Market Size Market Share Forecast by Regions (2023-2028)

Table 50. Global Recurrent Glioblastoma Multiforme Treatment Market Size Forecast by Type (2023-2028) & ($ Millions)

Table 51. Global Recurrent Glioblastoma Multiforme Treatment Market Size Market Share Forecast by Type (2023-2028)

Table 52. Global Recurrent Glioblastoma Multiforme Treatment Market Size Forecast by Application (2023-2028) & ($ Millions)

Table 53. Global Recurrent Glioblastoma Multiforme Treatment Market Size Market Share Forecast by Application (2023-2028)

Table 54. Boehringer Ingelheim GmbH Details, Company Type, Recurrent Glioblastoma Multiforme Treatment Area Served and Its Competitors

Table 55. Boehringer Ingelheim GmbH Recurrent Glioblastoma Multiforme Treatment Product Offered

Table 56. Boehringer Ingelheim GmbH Recurrent Glioblastoma Multiforme Treatment Revenue ($ million), Gross Margin and Market Share (2020-2022)

Table 57. Boehringer Ingelheim GmbH Main Business

Table 58. Boehringer Ingelheim GmbH Latest Developments

Table 59. Boston Biomedical, Inc. Details, Company Type, Recurrent Glioblastoma Multiforme Treatment Area Served and Its Competitors

Table 60. Boston Biomedical, Inc. Recurrent Glioblastoma Multiforme Treatment Product Offered

Table 61. Boston Biomedical, Inc. Main Business

Table 62. Boston Biomedical, Inc. Recurrent Glioblastoma Multiforme Treatment Revenue ($ million), Gross Margin and Market Share (2020-2022)

Table 63. Boston Biomedical, Inc. Latest Developments

Table 64. Bristol-Myers Squibb Company Details, Company Type, Recurrent Glioblastoma Multiforme Treatment Area Served and Its Competitors

Table 65. Bristol-Myers Squibb Company Recurrent Glioblastoma Multiforme Treatment Product Offered

Table 66. Bristol-Myers Squibb Company Main Business

Table 67. Bristol-Myers Squibb Company Recurrent Glioblastoma Multiforme Treatment Revenue ($ million), Gross Margin and Market Share (2020-2022)

Table 68. Bristol-Myers Squibb Company Latest Developments

Table 69. Cantex Pharmaceuticals, Inc. Details, Company Type, Recurrent Glioblastoma Multiforme Treatment Area Served and Its Competitors

Table 70. Cantex Pharmaceuticals, Inc. Recurrent Glioblastoma Multiforme Treatment Product Offered

Table 71. Cantex Pharmaceuticals, Inc. Main Business

Table 72. Cantex Pharmaceuticals, Inc. Recurrent Glioblastoma Multiforme Treatment Revenue ($ million), Gross Margin and Market Share (2020-2022)

Table 73. Cantex Pharmaceuticals, Inc. Latest Developments

Table 74. Cavion LLC Details, Company Type, Recurrent Glioblastoma Multiforme Treatment Area Served and Its Competitors

Table 75. Cavion LLC Recurrent Glioblastoma Multiforme Treatment Product Offered

Table 76. Cavion LLC Main Business

Table 77. Cavion LLC Recurrent Glioblastoma Multiforme Treatment Revenue ($ million), Gross Margin and Market Share (2020-2022)

Table 78. Cavion LLC Latest Developments

Table 79. Celldex Therapeutics, Inc. Details, Company Type, Recurrent Glioblastoma Multiforme Treatment Area Served and Its Competitors

Table 80. Celldex Therapeutics, Inc. Recurrent Glioblastoma Multiforme Treatment Product Offered

Table 81. Celldex Therapeutics, Inc. Main Business

Table 82. Celldex Therapeutics, Inc. Recurrent Glioblastoma Multiforme Treatment Revenue ($ million), Gross Margin and Market Share (2020-2022)

Table 83. Celldex Therapeutics, Inc. Latest Developments

Table 84. Coherus BioSciences, Inc. Details, Company Type, Recurrent Glioblastoma Multiforme Treatment Area Served and Its Competitors

Table 85. Coherus BioSciences, Inc. Recurrent Glioblastoma Multiforme Treatment Product Offered

Table 86. Coherus BioSciences, Inc. Main Business

Table 87. Coherus BioSciences, Inc. Recurrent Glioblastoma Multiforme Treatment Revenue ($ million), Gross Margin and Market Share (2020-2022)

Table 88. Coherus BioSciences, Inc. Latest Developments

Table 89. Cortice Biosciences, Inc. Details, Company Type, Recurrent Glioblastoma Multiforme Treatment Area Served and Its Competitors

Table 90. Cortice Biosciences, Inc. Recurrent Glioblastoma Multiforme Treatment Product Offered

Table 91. Cortice Biosciences, Inc. Main Business

Table 92. Cortice Biosciences, Inc. Recurrent Glioblastoma Multiforme Treatment Revenue ($ million), Gross Margin and Market Share (2020-2022)

Table 93. Cortice Biosciences, Inc. Latest Developments

Table 94. Eisai Details, Company Type, Recurrent Glioblastoma Multiforme Treatment Area Served and Its Competitors

Table 95. Eisai Recurrent Glioblastoma Multiforme Treatment Product Offered

Table 96. Eisai Main Business

Table 97. Eisai Recurrent Glioblastoma Multiforme Treatment Revenue ($ million), Gross Margin and Market Share (2020-2022)

Table 98. Eisai Latest Developments

Table 99. Eli Lilly and Company Details, Company Type, Recurrent Glioblastoma Multiforme Treatment Area Served and Its Competitors

Table 100. Eli Lilly and Company Recurrent Glioblastoma Multiforme Treatment Product Offered

Table 101. Eli Lilly and Company Main Business

Table 102. Eli Lilly and Company Recurrent Glioblastoma Multiforme Treatment Revenue ($ million), Gross Margin and Market Share (2020-2022)

Table 103. Eli Lilly and Company Latest Developments

Table 104. EnGeneIC Ltd Details, Company Type, Recurrent Glioblastoma Multiforme Treatment Area Served and Its Competitors

Table 105. EnGeneIC Ltd Recurrent Glioblastoma Multiforme Treatment Product Offered

Table 106. EnGeneIC Ltd Recurrent Glioblastoma Multiforme Treatment Revenue ($ million), Gross Margin and Market Share (2020-2022)

Table 107. EnGeneIC Ltd Main Business

Table 108. EnGeneIC Ltd Latest Developments

Table 109. ERC Belgium SA Details, Company Type, Recurrent Glioblastoma Multiforme Treatment Area Served and Its Competitors

Table 110. ERC Belgium SA Recurrent Glioblastoma Multiforme Treatment Product Offered

Table 111. ERC Belgium SA Main Business

Table 112. ERC Belgium SA Recurrent Glioblastoma Multiforme Treatment Revenue ($ million), Gross Margin and Market Share (2020-2022)

Table 113. ERC Belgium SA Latest Developments

Table 114. GenSpera, Inc. Details, Company Type, Recurrent Glioblastoma Multiforme Treatment Area Served and Its Competitors

Table 115. GenSpera, Inc. Recurrent Glioblastoma Multiforme Treatment Product Offered

Table 116. GenSpera, Inc. Main Business

Table 117. GenSpera, Inc. Recurrent Glioblastoma Multiforme Treatment Revenue ($ million), Gross Margin and Market Share (2020-2022)

Table 118. GenSpera, Inc. Latest Developments

Table 119. Genzyme Corporation Details, Company Type, Recurrent Glioblastoma Multiforme Treatment Area Served and Its Competitors

Table 120. Genzyme Corporation Recurrent Glioblastoma Multiforme Treatment Product Offered

Table 121. Genzyme Corporation Main Business

Table 122. Genzyme Corporation Recurrent Glioblastoma Multiforme Treatment Revenue ($ million), Gross Margin and Market Share (2020-2022)

Table 123. Genzyme Corporation Latest Developments

Table 124. GW Pharmaceuticals Plc Details, Company Type, Recurrent Glioblastoma Multiforme Treatment Area Served and Its Competitors

Table 125. GW Pharmaceuticals Plc Recurrent Glioblastoma Multiforme Treatment Product Offered

Table 126. GW Pharmaceuticals Plc Main Business

Table 127. GW Pharmaceuticals Plc Recurrent Glioblastoma Multiforme Treatment Revenue ($ million), Gross Margin and Market Share (2020-2022)

Table 128. GW Pharmaceuticals Plc Latest Developments

Table 129. ImmunoCellular Therapeutics, Ltd. Details, Company Type, Recurrent Glioblastoma Multiforme Treatment Area Served and Its Competitors

Table 130. ImmunoCellular Therapeutics, Ltd. Recurrent Glioblastoma Multiforme Treatment Product Offered

Table 131. ImmunoCellular Therapeutics, Ltd. Main Business

Table 132. ImmunoCellular Therapeutics, Ltd. Recurrent Glioblastoma Multiforme Treatment Revenue ($ million), Gross Margin and Market Share (2020-2022)

Table 133. ImmunoCellular Therapeutics, Ltd. Latest Developments

List of Figures

Figure 1. Recurrent Glioblastoma Multiforme Treatment Report Years Considered

Figure 2. Research Objectives

Figure 3. Research Methodology

Figure 4. Research Process and Data Source

Figure 5. Global Recurrent Glioblastoma Multiforme Treatment Market Size Growth Rate 2017-2028 ($ Millions)

Figure 6. Global Recurrent Glioblastoma Multiforme Treatment Market Size Market Share by Type in 2021

Figure 7. Recurrent Glioblastoma Multiforme Treatment in Hospital

Figure 8. Global Recurrent Glioblastoma Multiforme Treatment Market: Hospital (2017-2022) & ($ Millions)

Figure 9. Recurrent Glioblastoma Multiforme Treatment in Clinic

Figure 10. Global Recurrent Glioblastoma Multiforme Treatment Market: Clinic (2017-2022) & ($ Millions)

Figure 11. Recurrent Glioblastoma Multiforme Treatment in Others

Figure 12. Global Recurrent Glioblastoma Multiforme Treatment Market: Others (2017-2022) & ($ Millions)

Figure 13. Global Recurrent Glioblastoma Multiforme Treatment Market Size Market Share by Application in 2021

Figure 14. Global Recurrent Glioblastoma Multiforme Treatment Revenue Market Share by Player in 2021

Figure 15. Global Recurrent Glioblastoma Multiforme Treatment Market Size Market Share by Regions (2017-2022)

Figure 16. Americas Recurrent Glioblastoma Multiforme Treatment Market Size 2017-2022 ($ Millions)

Figure 17. APAC Recurrent Glioblastoma Multiforme Treatment Market Size 2017-2022 ($ Millions)

Figure 18. Europe Recurrent Glioblastoma Multiforme Treatment Market Size 2017-2022 ($ Millions)

Figure 19. Middle East & Africa Recurrent Glioblastoma Multiforme Treatment Market Size 2017-2022 ($ Millions)

Figure 20. Americas Recurrent Glioblastoma Multiforme Treatment Value Market Share by Country in 2021

Figure 21. Americas Recurrent Glioblastoma Multiforme Treatment Consumption Market Share by Type in 2021

Figure 22. Americas Recurrent Glioblastoma Multiforme Treatment Market Size Market Share by Application in 2021

Figure 23. United States Recurrent Glioblastoma Multiforme Treatment Market Size Growth 2017-2022 ($ Millions)

Figure 24. Canada Recurrent Glioblastoma Multiforme Treatment Market Size Growth 2017-2022 ($ Millions)

Figure 25. Mexico Recurrent Glioblastoma Multiforme Treatment Market Size Growth 2017-2022 ($ Millions)

Figure 26. Brazil Recurrent Glioblastoma Multiforme Treatment Market Size Growth 2017-2022 ($ Millions)

Figure 27. APAC Recurrent Glioblastoma Multiforme Treatment Market Size Market Share by Region in 2021

Figure 28. APAC Recurrent Glioblastoma Multiforme Treatment Market Size Market Share by Application in 2021

Figure 29. China Recurrent Glioblastoma Multiforme Treatment Market Size Growth 2017-2022 ($ Millions)

Figure 30. Japan Recurrent Glioblastoma Multiforme Treatment Market Size Growth 2017-2022 ($ Millions)

Figure 31. Korea Recurrent Glioblastoma Multiforme Treatment Market Size Growth 2017-2022 ($ Millions)

Figure 32. Southeast Asia Recurrent Glioblastoma Multiforme Treatment Market Size Growth 2017-2022 ($ Millions)

Figure 33. India Recurrent Glioblastoma Multiforme Treatment Market Size Growth 2017-2022 ($ Millions)

Figure 34. Australia Recurrent Glioblastoma Multiforme Treatment Market Size Growth 2017-2022 ($ Millions)

Figure 35. Europe Recurrent Glioblastoma Multiforme Treatment Market Size Market Share by Country in 2021

Figure 36. Europe Recurrent Glioblastoma Multiforme Treatment Market Size Market Share by Type in 2021

Figure 37. Europe Recurrent Glioblastoma Multiforme Treatment Market Size Market Share by Application in 2021

Figure 38. Germany Recurrent Glioblastoma Multiforme Treatment Market Size Growth 2017-2022 ($ Millions)

Figure 39. France Recurrent Glioblastoma Multiforme Treatment Market Size Growth 2017-2022 ($ Millions)

Figure 40. UK Recurrent Glioblastoma Multiforme Treatment Market Size Growth 2017-2022 ($ Millions)

Figure 41. Italy Recurrent Glioblastoma Multiforme Treatment Market Size Growth 2017-2022 ($ Millions)

Figure 42. Russia Recurrent Glioblastoma Multiforme Treatment Market Size Growth 2017-2022 ($ Millions)

Figure 43. Middle East & Africa Recurrent Glioblastoma Multiforme Treatment Market Size Market Share by Region in 2021

Figure 44. Middle East & Africa Recurrent Glioblastoma Multiforme Treatment Market Size Market Share by Type in 2021

Figure 45. Middle East & Africa Recurrent Glioblastoma Multiforme Treatment Market Size Market Share by Application in 2021

Figure 46. Egypt Recurrent Glioblastoma Multiforme Treatment Market Size Growth 2017-2022 ($ Millions)

Figure 47. South Africa Recurrent Glioblastoma Multiforme Treatment Market Size Growth 2017-2022 ($ Millions)

Figure 48. Israel Recurrent Glioblastoma Multiforme Treatment Market Size Growth 2017-2022 ($ Millions)

Figure 49. Turkey Recurrent Glioblastoma Multiforme Treatment Market Size Growth 2017-2022 ($ Millions)

Figure 50. GCC Country Recurrent Glioblastoma Multiforme Treatment Market Size Growth 2017-2022 ($ Millions)

Figure 51. Americas Recurrent Glioblastoma Multiforme Treatment Market Size 2023-2028 ($ Millions)

Figure 52. APAC Recurrent Glioblastoma Multiforme Treatment Market Size 2023-2028 ($ Millions)

Figure 53. Europe Recurrent Glioblastoma Multiforme Treatment Market Size 2023-2028 ($ Millions)

Figure 54. Middle East & Africa Recurrent Glioblastoma Multiforme Treatment Market Size 2023-2028 ($ Millions)

Figure 55. United States Recurrent Glioblastoma Multiforme Treatment Market Size 2023-2028 ($ Millions)

Figure 56. Canada Recurrent Glioblastoma Multiforme Treatment Market Size 2023-2028 ($ Millions)

Figure 57. Mexico Recurrent Glioblastoma Multiforme Treatment Market Size 2023-2028 ($ Millions)

Figure 58. Brazil Recurrent Glioblastoma Multiforme Treatment Market Size 2023-2028 ($ Millions)

Figure 59. China Recurrent Glioblastoma Multiforme Treatment Market Size 2023-2028 ($ Millions)

Figure 60. Japan Recurrent Glioblastoma Multiforme Treatment Market Size 2023-2028 ($ Millions)

Figure 61. Korea Recurrent Glioblastoma Multiforme Treatment Market Size 2023-2028 ($ Millions)

Figure 62. Southeast Asia Recurrent Glioblastoma Multiforme Treatment Market Size 2023-2028 ($ Millions)

Figure 63. India Recurrent Glioblastoma Multiforme Treatment Market Size 2023-2028 ($ Millions)

Figure 64. Australia Recurrent Glioblastoma Multiforme Treatment Market Size 2023-2028 ($ Millions)

Figure 65. Germany Recurrent Glioblastoma Multiforme Treatment Market Size 2023-2028 ($ Millions)

Figure 66. France Recurrent Glioblastoma Multiforme Treatment Market Size 2023-2028 ($ Millions)

Figure 67. UK Recurrent Glioblastoma Multiforme Treatment Market Size 2023-2028 ($ Millions)

Figure 68. Italy Recurrent Glioblastoma Multiforme Treatment Market Size 2023-2028 ($ Millions)

Figure 69. Russia Recurrent Glioblastoma Multiforme Treatment Market Size 2023-2028 ($ Millions)

Figure 70. Spain Recurrent Glioblastoma Multiforme Treatment Market Size 2023-2028 ($ Millions)

Figure 71. Egypt Recurrent Glioblastoma Multiforme Treatment Market Size 2023-2028 ($ Millions)

Figure 72. South Africa Recurrent Glioblastoma Multiforme Treatment Market Size 2023-2028 ($ Millions)

Figure 73. Israel Recurrent Glioblastoma Multiforme Treatment Market Size 2023-2028 ($ Millions)

Figure 74. Turkey Recurrent Glioblastoma Multiforme Treatment Market Size 2023-2028 ($ Millions)

Figure 75. GCC Countries Recurrent Glioblastoma Multiforme Treatment Market Size 2023-2028 ($ Millions)